News Conference News VIVA 2024 Amputations Still Avoided With Flow-Diverting Therapy for CLTI at 2 Years: PROMISE II L.A. McKeown November 06, 2024
News Conference News VIVA 2024 Disappearing Scaffold for CLTI Still Works Well at 2 Years: LIFE-BTK L.A. McKeown November 05, 2024
News Conference News VIVA 2022 TRANSCEND: Low-Dose DCB for PAD Still Looking Good at 2 Years L.A. McKeown November 03, 2022
News Conference News VIVA 2021 EMINENT: Better Patency With DES Over BMS for Fem-Pop Lesions L.A. McKeown October 12, 2021
News Conference News VIVA 2019 Nearly 1 Year Later, Endovascular Community Continues to Struggle With Paclitaxel L.A. McKeown November 08, 2019
News Conference News VIVA 2018 IMPERIAL Substudy Provides Reassurance for Benefit of Eluvia in Long Lesions L.A. McKeown November 06, 2018